Latest news
Debiopharm Strategic Fund announces FDA clearance of Portfolio Company Immunexpress’ first Test
Debiopharm International SA Appeals to the Supreme Court regarding Nippon Kayaku Co., Ltd. case
Debiopharm Investment strengthens its presence in the renewable energy sector
GenePOC to Announce CE Marking of its revogene™ Instrument and its Second Test, CDiff
Debiopharm International SA Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients
Debiopharm Group’s Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe
Les projets «Hello Mask» et «Le 5ème mur» remportent le Challenge Debiopharm-Inartis 2016 sur la Qualité de Vie des Patients
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.